Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 01 2025
0mins
Should l Buy FLGT?
Source: SeekingAlpha
Core Revenue $81.7 million, up 16% year-over-year and 11% sequentially. The increase was driven by strong performance across all business areas, including Precision Diagnostics (up 7%), Biopharma Services (up 54%), and Anatomic Pathology (up 11%).
Gross Margin (Non-GAAP) 44.2%, improved year-over-year and sequentially due to streamlined operations, enhanced efficiency, and certain onetime adjustments.
Operating Expenses (Non-GAAP) $43.9 million, up from $37.4 million in Q1 2025. The increase was due to higher R&D spending for clinical studies and increased sales and marketing costs.
Operating Margin (Non-GAAP) -9.4%, slightly improved sequentially.
GAAP Loss $19 million, including a onetime noncash charge of $9.9 million for impairment of a prior investment.
Adjusted EBITDA Loss $3 million, compared to a loss of $2.9 million in Q1 2025.
Non-GAAP Income $2.1 million or $0.07 per share, excluding equity-based compensation, intangible asset amortization, and impairment loss.
Cash Position $777.5 million in cash, cash equivalents, restricted cash, and marketable securities. Cash usage included $31.7 million for income tax credits and $2.2 million for stock repurchase.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FLGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FLGT
Wall Street analysts forecast FLGT stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 13.790
Low
30.00
Averages
32.50
High
35.00
Current: 13.790
Low
30.00
Averages
32.50
High
35.00
About FLGT
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulgent Genetics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Fulgent Genetics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further declines in stock price.
- Poor Financial Performance: Fulgent's financial results released on February 27, 2026, revealed lower-than-expected performance for Q4 and the full year 2025, particularly with disappointing guidance for 2026 due to its largest customer moving significant work in-house.
- Stock Price Plunge: Following this news, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting the market's pessimism regarding the company's future prospects.
- Potential Legal Consequences: Should the investigation confirm misconduct by Fulgent and its executives, the company may face class action lawsuits, further damaging its reputation and impacting future financing capabilities.
See More
Fulgent Genetics Under Investigation for Potential Investor Claims
- Earnings Miss: Fulgent Genetics reported approximately $322.7 million in full-year 2025 revenue, slightly below the updated guidance, indicating pressure on the company's market position.
- Customer Concentration Risk: The transition of Fulgent's largest customer to in-house testing led to a decline in fourth-quarter revenue, with this customer accounting for 22% of total revenue in 2025, highlighting the risks associated with reliance on a single client.
- Uncertain Outlook: The anticipated significant impact on revenue in the first half of 2026 due to customer transition has shaken investor confidence in future performance, resulting in a decline in stock price.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Fulgent complied with federal securities laws, encouraging investors who suffered losses from Fulgent stock to join the investigation for potential recovery.
See More
FULGENT GENETICS INC: UBS Lowers Price Target from $35 to $22
Company Overview: Fulgen Genetics is a company focused on genetic testing and related services.
Stock Price Change: The target price for Fulgen Genetics has been reduced from $35 to $22.
See More
Fulgent Genetics Q4 2025 Earnings Call Insights
- Revenue Growth: Fulgent Genetics reported fourth-quarter revenue of $83.3 million, a 9% year-over-year increase, with full-year revenue reaching $322.7 million, up 14%, indicating ongoing progress in laboratory services and therapeutic development.
- Technology Investment Returns: The launch of the proprietary imaging management system Eziopath, along with the integration of RNA whole genome sequencing and ultra-rapid sequencing, is expected to drive revenue and margin improvements, further solidifying the company's leadership in digital pathology and AI.
- Customer Concentration Risk: The transition of the largest customer to in-house processing is anticipated to result in revenue loss, but management expects to offset this through acquisitions of Bako and StrataDx, projecting additional revenue of $50 to $55 million from these deals.
- Future Outlook: Projected revenue for 2026 is $350 million, representing an 8.5% year-over-year growth, and despite facing margin pressure, management maintains strong confidence in their technology platform and product innovations, which are expected to support long-term revenue growth and improved operating leverage.
See More
First Horizon and Oracle Options Show High Trading Volume
- First Horizon Options Activity: First Horizon Corp (FHN) has seen an options volume of 41,552 contracts today, representing approximately 4.2 million underlying shares, which accounts for 62.7% of its average daily trading volume of 6.6 million shares over the past month, indicating a significant increase in market interest.
- High Call Option Volume: The $26 strike call option for FHN has traded 20,162 contracts today, equating to about 2.0 million shares, suggesting that investors are increasingly optimistic about future price increases, which could influence market sentiment.
- Oracle Options Activity: Oracle Corp (ORCL) has recorded an options volume of 188,976 contracts today, representing approximately 18.9 million underlying shares, which is 62.3% of its average daily trading volume of 30.3 million shares over the past month, reflecting strong investor interest in the company.
- High Put Option Volume: The $116 strike put option for ORCL has seen 13,635 contracts traded today, representing around 1.4 million shares, indicating market concerns about potential future price declines, which may affect investor decision-making.
See More
U.S. Stocks Decline Midway; Dell Shares Surge Over 21%
- Market Performance: U.S. stocks traded lower midway through the session, with the Nasdaq Composite falling over 1%, the Dow down 1.40% to 48,807.06, and the S&P 500 dropping 0.74% to 6,858.05, indicating overall market weakness.
- Dell's Earnings Beat: Dell Technologies Inc. (NYSE:DELL) shares surged over 21% on Friday after reporting fourth-quarter earnings of $3.89 per share, exceeding the consensus estimate of $3.53, with quarterly revenue hitting $33.38 billion, up from $23.93 billion a year ago, showcasing strong financial performance.
- Sector Dynamics: Consumer staples stocks rose by 1.3%, while financial stocks fell by 2.6%, reflecting mixed reactions across sectors that could influence investors' asset allocation strategies.
- Commodity Market Fluctuations: Oil prices increased by 2% to $66.54, gold rose by 1.1% to $5,252.30, and silver jumped 7.7% to $94.360, indicating active commodity markets and heightened demand for safe-haven assets.
See More
Fulgent Genetics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Fulgent Genetics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further declines in stock price.
- Poor Financial Performance: Fulgent's financial results released on February 27, 2026, revealed lower-than-expected performance for Q4 and the full year 2025, particularly with disappointing guidance for 2026 due to its largest customer moving significant work in-house.
- Stock Price Plunge: Following this news, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting the market's pessimism regarding the company's future prospects.
- Potential Legal Consequences: Should the investigation confirm misconduct by Fulgent and its executives, the company may face class action lawsuits, further damaging its reputation and impacting future financing capabilities.
See More
Fulgent Genetics Under Investigation for Potential Investor Claims
- Earnings Miss: Fulgent Genetics reported approximately $322.7 million in full-year 2025 revenue, slightly below the updated guidance, indicating pressure on the company's market position.
- Customer Concentration Risk: The transition of Fulgent's largest customer to in-house testing led to a decline in fourth-quarter revenue, with this customer accounting for 22% of total revenue in 2025, highlighting the risks associated with reliance on a single client.
- Uncertain Outlook: The anticipated significant impact on revenue in the first half of 2026 due to customer transition has shaken investor confidence in future performance, resulting in a decline in stock price.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Fulgent complied with federal securities laws, encouraging investors who suffered losses from Fulgent stock to join the investigation for potential recovery.
See More
FULGENT GENETICS INC: UBS Lowers Price Target from $35 to $22
Company Overview: Fulgen Genetics is a company focused on genetic testing and related services.
Stock Price Change: The target price for Fulgen Genetics has been reduced from $35 to $22.
See More
Fulgent Genetics Q4 2025 Earnings Call Insights
- Revenue Growth: Fulgent Genetics reported fourth-quarter revenue of $83.3 million, a 9% year-over-year increase, with full-year revenue reaching $322.7 million, up 14%, indicating ongoing progress in laboratory services and therapeutic development.
- Technology Investment Returns: The launch of the proprietary imaging management system Eziopath, along with the integration of RNA whole genome sequencing and ultra-rapid sequencing, is expected to drive revenue and margin improvements, further solidifying the company's leadership in digital pathology and AI.
- Customer Concentration Risk: The transition of the largest customer to in-house processing is anticipated to result in revenue loss, but management expects to offset this through acquisitions of Bako and StrataDx, projecting additional revenue of $50 to $55 million from these deals.
- Future Outlook: Projected revenue for 2026 is $350 million, representing an 8.5% year-over-year growth, and despite facing margin pressure, management maintains strong confidence in their technology platform and product innovations, which are expected to support long-term revenue growth and improved operating leverage.
See More
First Horizon and Oracle Options Show High Trading Volume
- First Horizon Options Activity: First Horizon Corp (FHN) has seen an options volume of 41,552 contracts today, representing approximately 4.2 million underlying shares, which accounts for 62.7% of its average daily trading volume of 6.6 million shares over the past month, indicating a significant increase in market interest.
- High Call Option Volume: The $26 strike call option for FHN has traded 20,162 contracts today, equating to about 2.0 million shares, suggesting that investors are increasingly optimistic about future price increases, which could influence market sentiment.
- Oracle Options Activity: Oracle Corp (ORCL) has recorded an options volume of 188,976 contracts today, representing approximately 18.9 million underlying shares, which is 62.3% of its average daily trading volume of 30.3 million shares over the past month, reflecting strong investor interest in the company.
- High Put Option Volume: The $116 strike put option for ORCL has seen 13,635 contracts traded today, representing around 1.4 million shares, indicating market concerns about potential future price declines, which may affect investor decision-making.
See More
U.S. Stocks Decline Midway; Dell Shares Surge Over 21%
- Market Performance: U.S. stocks traded lower midway through the session, with the Nasdaq Composite falling over 1%, the Dow down 1.40% to 48,807.06, and the S&P 500 dropping 0.74% to 6,858.05, indicating overall market weakness.
- Dell's Earnings Beat: Dell Technologies Inc. (NYSE:DELL) shares surged over 21% on Friday after reporting fourth-quarter earnings of $3.89 per share, exceeding the consensus estimate of $3.53, with quarterly revenue hitting $33.38 billion, up from $23.93 billion a year ago, showcasing strong financial performance.
- Sector Dynamics: Consumer staples stocks rose by 1.3%, while financial stocks fell by 2.6%, reflecting mixed reactions across sectors that could influence investors' asset allocation strategies.
- Commodity Market Fluctuations: Oil prices increased by 2% to $66.54, gold rose by 1.1% to $5,252.30, and silver jumped 7.7% to $94.360, indicating active commodity markets and heightened demand for safe-haven assets.
See More
